RNAi / siRNA Deal Benchmarks in Hematology
Market Analysis
RNAi / siRNA therapies in hematology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,400+ verified transactions, the median upfront payment for a Phase 2 rnai / sirna asset in hematology is $695M, with total deal values reaching $3.4B. Development milestones average $574M, while regulatory milestones contribute $684M.
The hematology rnai / sirna landscape is characterized by high competitive intensity in lymphoma and myeloma with established treatment paradigms. Bispecific antibodies and next-generation cell therapies are displacing traditional chemotherapy combinations. The recommended deal structure allocates approximately 20% to upfront payments and 80% to milestones, reflecting the risk-reward profile at the Phase 2 stage.
Royalty rates for rnai / sirna hematology deals range from 8.9% to 16.7% at the base tier, with tiered escalation reaching 12.9%-20.7% on blockbuster sales. Commercial milestones averaging $1.5B further reward successful market penetration.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What is the typical upfront for a rnai / sirna hematology licensing deal?
What is the total deal value for rnai / sirna hematology transactions?
What royalty rates are standard for rnai / sirna deals in hematology?
How are milestones structured in rnai / sirna hematology deals?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.